VentriPoint Diagnostics (TSE:VPT) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Ventripoint Diagnostics and ASCEND Cardiovascular have signed a term sheet for a non-exclusive license to integrate Ventripoint’s VMS+ technology into ASCEND’s Gen3Echo platform, aiming to enhance cardiovascular diagnostics. This collaboration promises to improve diagnostic accuracy and streamline workflows for echocardiographers by combining cutting-edge AI and machine learning technologies.
For further insights into TSE:VPT stock, check out TipRanks’ Stock Analysis page.
